Treatment with Kalydeco (ivacaftor) improved lung function, exercise capacity, and sweat chloride concentration in cystic fibrosis (CF) patients with severe lung…
Articles by Patricia Inácio, PhD
Long-term use of inhaled antibiotics, given to treat lung infections caused by the bacteria Pseudomonas aeruginosa in people with cystic…
Treatment with Orkambi significantly improves exercise tolerance in adult cystic fibrosis patients with severe disease as early as…
Data from Phase 1 studies in healthy people and preclinical work indicate that ELX-02 may help to treat cystic…
Inhalation of nitric oxide as an add-on therapy may help reduce the burden of serious bacterial lung infections, namely the…
Long-term treatment with Kalydeco (ivacaftor) is well-tolerated and efficient, with improvements in sweat chloride concentration, growth, and pancreas function…
A mouse model carrying the most common mutation in the CFTR gene (the gene defective in patients with cystic fibrosis) shows…
Poor oxygen conditions, a common trait in the lungs of cystic fibrosis (CF) patients, may help Pseudomonas aeruginosa…
The RESTORE-CF clinical trial investigating Translate Bio’s candidate therapy MRT5005 has completed the single-ascending dose regimen in patients with cystic…
Using the gene editing tool CRISPR-Cas9 to specifically target the lung of a developing fetus, researchers were able to correct…